An article in the July 2016 issue, “Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma” by Gaurav Varma, MSPH, Tyler P. Johnson, MD, and Ranjana H. Advani, MD, described ONO/GS-4059 as a “reversible” inhibitor of BTK when it is in fact an “irreversible” inhibitor. We have made the correction to pages 546 and 552 of the online version at www.hematologyandoncology.net. Many thanks to an astute reader for pointing out the error.